Evidence map›Paper›PMID 38976022›Full record

ArticleArchives of gynecology and obstetrics2024

Fertility-sparing strategy in a rare case of highly malignant Dicer-1-associated sarcoma of the cervix.

J Altmann, K Kubiak, J Sehouli, E Roser

Abstract readCase Reports
In one paragraph

Article in Archives of gynecology and obstetrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

J Altmann *Department of Gynecology with Center of Oncological Surgery, Charité-University Hospital Berlin, Charitéplatz 1, 10117, Berlin, Germany. judith.altmann@charite.de.ORCID 0000-0003-2065-5058
K Kubiak *Department of Gynecology, St-Franziskus Hospital, Münster, Germany.
J SehouliDepartment of Gynecology with Center of Oncological Surgery, Charité-University Hospital Berlin, Charitéplatz 1, 10117, Berlin, Germany.
E RoserDepartment of Gynecology with Center of Oncological Surgery, Charité-University Hospital Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe present the rare case of an 18-year-old patient with a Dicer-1 mutation-associated sarcoma of the cervix uteri. CASE: The patient presented with irregular vaginal bleeding in July 2022. The clinical examination showed an exophytic tumor of the cervix, uterus and ovaries were normal in sonogram. The tumor of the cervix was resected, followed by a diagnostic hysteroscopy and abrasion of the uterine cervix and cavity. Hysteroscopy showed normal findings of the cervix and uterus. After diagnosis of a highly malignant Dicer-1 mutation-associated sarcoma of the cervix, cryopreservation of oocytes was realized. Based on the principle of obtaining maximum oncological safety while preserving fertility in this 18-year-old patient, we recommended chemotherapy rather than radiation with its far severe implications on the patient´s reproductive organs. 4 cycles of chemotherapy consisting of doxorubicin and ifosfamide were applied until December 2022. After re-staging in December 2022 via CT scan and MRI, the abdomen and pelvis as well as control hysteroscopy and abrasion were unremarkable. Until now, the patient is tumor free. DISCUSSION: Primary sarcomas of the cervix are very rare. Recent literature hints towards a distinct DICER-1 sarcoma entity characterized by specific mutational clusters. Limited follow-up data suggested that DICER1-mutant tumors might exhibit a less aggressive clinical course than DICER1-wild-type tumors.

conclusionDecision-making in case of rare histological entities with sparse recommendations in the literature poses a challenge to the treating physician. Treatment strategies should consider oncological safety as well as options of preserving fertility. Gonadotoxic potential of different strategies should be taken into consideration and discussed in detail with the affected patient.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsFertilityRibonuclease IIISarcomaUterine Cervical NeoplasmsAdolescentDEAD-box RNA HelicasesDoxorubicinHumansIfosfamideMagnetic Resonance ImagingMutationTomography, X-Ray ComputedTreatment OutcomeDEAD-box RNA HelicasesDICER1 protein, humanDoxorubicinIfosfamideRibonuclease IIICervical sarcomaDicer-1 sarcomaFertility preservationFertility sparing

Identifiers

PMID38976022
PMCPMC11485030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.